Abstract | AIM: Recently, a number of studies have demonstrated the effectiveness of a single reduced dose of rasburicase for the management of tumor lysis syndrome (TLS) in adults. Whether Asian lymphoma patients similarly respond to a single dose of rasburicase is currently unknown. We aim to assess the efficacy of a single dose rasburicase in preventing TLS in Asian lymphoma patients. METHODS: RESULTS: Eleven patients were identified. Majority were Chinese (91%), male (64%) and with a median age of 61 years (range 41-84). All had at least two risk factors for developing TLS. Ten patients received a 6-mg dose and one received 4.5 mg. Prior to rasburicase administration, the mean uric acid level was 835 µmol/L (range 318-1237 µmol/L) and the level 24-h post-administration was 186 µmol/L (range 30-653 µmol/L) (P < 0.001). Eight patients (73%) experienced an improvement of renal function 72-h post- rasburicase. Normalization of serum electrolytes was achieved within 96 h. CONCLUSION: Among Asian lymphoma patients who manifested at least two risk factors for developing TLS, a single fixed dose of rasburicase at 6 mg is deemed to be effective for rapidly lowering uric acid levels as well as sustaining reduced levels for up to 72 h.
|
Authors | Joen Chiang, Alexandre Chan, Tracy Lian, Kevin Tay, Richard Quek, Miriam Tao, Soon Thye Lim |
Journal | Asia-Pacific journal of clinical oncology
(Asia Pac J Clin Oncol)
Vol. 7
Issue 4
Pg. 351-6
(Dec 2011)
ISSN: 1743-7563 [Electronic] Australia |
PMID | 22151984
(Publication Type: Journal Article, Review)
|
Copyright | © 2011 Blackwell Publishing Asia Pty Ltd. |
Chemical References |
- rasburicase
- Uric Acid
- Creatinine
- L-Lactate Dehydrogenase
- Urate Oxidase
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Asia
- Burkitt Lymphoma
(blood, pathology)
- Creatinine
(blood)
- Female
- Humans
- L-Lactate Dehydrogenase
(blood)
- Lymphoma, Large B-Cell, Diffuse
(blood, pathology)
- Male
- Middle Aged
- Risk Factors
- Tumor Lysis Syndrome
(blood, drug therapy, pathology)
- Urate Oxidase
(therapeutic use)
- Uric Acid
(blood)
|